Video Experimental Relacionado
Updated: Aug 15, 2025
10:28
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
9.4K
De ABCD a E para la endotelina en la hipertensión resistente
George R Abraham1, Anthony P Davenport2
1Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Cell
|January 5, 2023
Resumen
La endotelina-1, un vasoconstrictor, regula el tono vascular. Los antagonistas de los receptores de endotelina son prometedores para el tratamiento de la hipertensión resistente, lo que podría marcar una nueva era clínica.
Área de la Ciencia:
- Farmacología cardiovascular
- Investigación de la hipertensión
Sus antecedentes:
- Endothelin-1 es un potente péptido vasoconstrictor que regula el tono vascular.
- El bloqueo farmacológico de la vía de la endotelina-1 tiene aplicaciones clínicas limitadas.
- La hipertensión resistente sigue siendo un desafío clínico significativo.
Objetivo del estudio:
- Evaluar la eficacia de los antagonistas de los receptores de la endotelina en pacientes con hipertensión resistente.
- Explorar el potencial de dirigirse a la vía de la endotelina-1 para el tratamiento de la hipertensión.
Principales métodos:
- Se analizó un ensayo clínico reciente que investigaba los antagonistas de los receptores de la endotelina.
- El estudio se centró en pacientes con hipertensión resistente al tratamiento.
Principales resultados:
- El ensayo clínico demostró una nueva función potencial para los antagonistas de los receptores de la endotelina.
- Los resultados sugieren que estos antagonistas pueden ser eficaces en el tratamiento de la hipertensión resistente.
Conclusiones:
- Los antagonistas de los receptores de endotelina pueden pasar a la práctica clínica convencional para la hipertensión resistente.
- Dirigirse a la vía de la endotelina-1 representa una estrategia terapéutica prometedora.
Videos de Conceptos Relacionados
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
215
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
215
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
753
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
753
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
808
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
808
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
481
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
01:29Hypertension II: Pathophysiology
34
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
34
01:25Antihypertensive Drugs: Direct Renin Inhibitors
731
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
731